Brief: Eloxx Pharmaceuticals Reports Fourth Quarter And Full Year 2020 Financial And Operating Results
11/03/2021 22:03
March 11 (Reuters) - Eloxx Pharmaceuticals Inc ELOX.O :
* ELOXX PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR
2020
FINANCIAL AND OPERATING RESULTS AND PROVIDES BUSINESS UPDATE
* Q4 LOSS PER SHARE $0.15
* Q4 EARNINGS PER SHARE ESTIMATE $-0.21 -- REFINITIV IBES
DATA
* EXPECT TO REPORT TOP LINE DATA FROM OUR PHASE 2 CYSTIC
FIBROSIS
CLINICAL TRIALS IN FIRST HALF OF THIS YEAR
* ELOXX PHARMA- QUARTER END CASH AND CASH EQUIVALENTS OF
$24.7
MILLION, WHICH WE EXPECT WILL BE SUFFICIENT TO FUND OPERATIONS
THOUGH TOP LINE DATA AND INTO Q4
Source text for Eikon: ID:nGNXlzMtL
Further company coverage: ELOX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eloxx Pharmaceuticals
See all newsNASDAQ RESUMED AT 02:24 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:19 PM
Brief: Eloxx Pharmaceuticals Provides ELX-02 And ZKN-013 Program Updates
Brief: Eloxx Pharmaceuticals Confirms That Alport Syndrome Patients Treated With Elx-02 In Phase 2 Study Had Improvement
Brief: Eloxx Pharmaceuticals Inc Reports Results In All Patients Treated With Elx-02 In Phase 2 Clinical Study For Alport Syndrome